1. Home
  2. CRBU vs VYGR Comparison

CRBU vs VYGR Comparison

Compare CRBU & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Caribou Biosciences Inc.

CRBU

Caribou Biosciences Inc.

HOLD

Current Price

$1.82

Market Cap

203.9M

Sector

Health Care

ML Signal

HOLD

Logo Voyager Therapeutics Inc.

VYGR

Voyager Therapeutics Inc.

HOLD

Current Price

$3.90

Market Cap

194.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRBU
VYGR
Founded
2011
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
203.9M
194.0M
IPO Year
2021
2015

Fundamental Metrics

Financial Performance
Metric
CRBU
VYGR
Price
$1.82
$3.90
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
6
Target Price
$10.00
$17.00
AVG Volume (30 Days)
1.2M
482.8K
Earning Date
06-08-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
3.64
N/A
EPS
N/A
N/A
Revenue
N/A
$10,135,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$5.37
$71.77
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.66
$2.65
52 Week High
$3.53
$5.55

Technical Indicators

Market Signals
Indicator
CRBU
VYGR
Relative Strength Index (RSI) 51.92 50.54
Support Level $1.71 $3.73
Resistance Level $2.11 $4.43
Average True Range (ATR) 0.15 0.24
MACD -0.01 0.04
Stochastic Oscillator 38.03 56.88

Price Performance

Historical Comparison
CRBU
VYGR

About CRBU Caribou Biosciences Inc.

Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.

About VYGR Voyager Therapeutics Inc.

Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.

Share on Social Networks: